Inclusion Criteria:

- Histologically confirmed unresectable, locally advanced (III A (bulky N2), III B)
lung adenocarcinoma

- No previous chemotherapy, radiotherapy, surgery or biological therapy for lung cancer

- Adequate organ and bone marrow function

Exclusion Criteria:

- Prior chemotherapy or radiation therapy for NSCLC

- Prior treatment with bevacizumab or other agents specifically targeting vascular
endothelial growth factor (VEGF)

- Patients with known hypersensitivity to other recombinant human antibodies

- History of stroke or transient ischemic attack (TIA).

- History of myocardial infarction or unstable angina within the past 12 months.

- Other serious illness or medical condition including unstable cardiac disease
requiring treatment, history of significant neurologic or psychiatric disorders
(including psychotic disorders, dementia, or seizures), symptomatic diverticulitis,
or active uncontrolled infection.

- Women who are pregnant or breast-feeding